TY - JOUR T1 - Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas JF - BMJ Open Respiratory Research JO - BMJ Open Resp Res DO - 10.1136/bmjresp-2019-000505 VL - 7 IS - 1 SP - e000505 AU - Emoke Papp AU - Anita Steib AU - Elhusseiny MM Abdelwahab AU - Judit Meggyes-Rapp AU - Laszlo Jakab AU - Gabor Smuk AU - Erzsebet Schlegl AU - Judit Moldvay AU - Veronika Sárosi AU - Judit E Pongracz Y1 - 2020/06/01 UR - http://bmjopenrespres.bmj.com/content/7/1/e000505.abstract N2 - Background Despite improved screening techniques, diagnosis of lung cancer is often late and its prognosis is poor. In the present study, in vitro chemosensitivity of solid tumours and pleural effusions of lung adenocarcinomas were analysed and compared with clinical drug response.Methods Tumour cells were isolated from resected solid tumours or pleural effusions, and cryopreserved. Three-dimensional (3D) tissue aggregate cultures were set up when the oncoteam reached therapy decision for individual patients. The aggregates were then treated with the selected drug or drug combination and in vitro chemosensitivity was tested individually measuring ATP levels. The clinical response to therapy was assessed by standard clinical evaluation over an 18 months period.Results Based on the data, the in vitro chemosensitivity test results correlate well with clinical treatment response.Conclusions Such tests if implemented into the clinical decision making process might allow the selection of an even more individualised chemotherapy protocol which could lead to better therapy response. ER -